SB408124 Property

Boiling point:

430.3±45.0 °C(Predicted)

Density 

1.371

storage temp. 

Sealed in dry,2-8°C

solubility 

DMSO: ~24 mg/mL

form 

solid

pka

12.12±0.43(Predicted)

color 

olive-green

Safety

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26-36

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

SB408124 Chemical Properties,Usage,Production

Uses

SB 408124 is a novel OX-1 antagonist.

Definition

ChEBI: 1-(6,8-difluoro-2-methyl-4-quinolinyl)-3-[4-(dimethylamino)phenyl]urea is a member of quinolines and an organohalogen compound.

Biological Activity

Selective non-peptide orexin OX 1 receptor antagonist (K b values are 21.7 and 1405 nM for human OX 1 and OX 2 receptors respectively). Blocks orexin-A induced grooming following oral administration in vivo .

storage

Store at RT

References

[1] langmead cj1, jerman jc, brough sj, scott c, porter ra, herdon hj.characterisation of the binding of [3h]-sb-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. br j pharmacol. 2004 jan;141(2):340-6.
[2] woldan-tambor a1, biegańska k, wiktorowska-owczarek a, zawilska jb. activation of orexin/hypocretin type 1 receptors stimulates camp synthesis in primary cultures of rat astrocytes. pharmacol rep. 2011;63(3):717-23.
[3] kis gk1, molnár ah, daruka l, gardi j, rákosi k, lászló f, lászló fa, varga c.the osmotically and histamine-induced enhancement of the plasma vasopressin level is diminished by intracerebroventricularly administered orexin in rats. pflugers arch. 2012 apr;463(4):531-6.